MEF2C Transcription Factor Controls Chondrocyte Hypertrophy and Bone Development

Michael A. Arnold, Yuri Kim, Michael P. Czubryt, Dillon Phan, John McAnally, Xiaoxia Qi, John M. Shelton, James A. Richardson, Rhonda Bassel-Duby, Eric N. Olson

Research output: Contribution to journalArticlepeer-review

330 Scopus citations


Chondrocyte hypertrophy is essential for endochondral bone development. Unexpectedly, we discovered that MEF2C, a transcription factor that regulates muscle and cardiovascular development, controls bone development by activating the gene program for chondrocyte hypertrophy. Genetic deletion of Mef2c or expression of a dominant-negative MEF2C mutant in endochondral cartilage impairs hypertrophy, cartilage angiogenesis, ossification, and longitudinal bone growth in mice. Conversely, a superactivating form of MEF2C causes precocious chondrocyte hypertrophy, ossification of growth plates, and dwarfism. Endochondral bone formation is exquisitely sensitive to the balance between MEF2C and the corepressor histone deacetylase 4 (HDAC4), such that bone deficiency of Mef2c mutant mice can be rescued by an Hdac4 mutation, and ectopic ossification in Hdac4 null mice can be diminished by a heterozygous Mef2c mutation. These findings reveal unexpected commonalities in the mechanisms governing muscle, cardiovascular, and bone development with respect to their regulation by MEF2 and class II HDACs.

Original languageEnglish (US)
Pages (from-to)377-389
Number of pages13
JournalDevelopmental cell
Issue number3
StatePublished - Mar 2007



ASJC Scopus subject areas

  • Molecular Biology
  • Biochemistry, Genetics and Molecular Biology(all)
  • Developmental Biology
  • Cell Biology


Dive into the research topics of 'MEF2C Transcription Factor Controls Chondrocyte Hypertrophy and Bone Development'. Together they form a unique fingerprint.

Cite this